The burgeoning landscape of novel treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a comparable https://businessbookmark.com/story6231799/retatrutide-vs-tirzepatide-a-comparative-analysis